PubRank

Robert C Green

Author PubWeight™ 194.32‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet 2011 10.07
2 The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat Genet 2007 9.80
3 Managing incidental findings and research results in genomic research involving biobanks and archived data sets. Genet Med 2012 9.65
4 Diagnostic clinical genome and exome sequencing. N Engl J Med 2014 5.55
5 Protective variant for hippocampal atrophy identified by whole exome sequencing. Ann Neurol 2015 5.10
6 The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement 2011 4.25
7 Clinical Core of the Alzheimer's Disease Neuroimaging Initiative: progress and plans. Alzheimers Dement 2010 3.11
8 The Scientific Foundation for personal genomics: recommendations from a National Institutes of Health-Centers for Disease Control and Prevention multidisciplinary workshop. Genet Med 2009 2.91
9 Estimating risk curves for first-degree relatives of patients with Alzheimer's disease: the REVEAL study. Genet Med 2004 2.82
10 Alzheimer's Disease Neuroimaging Initiative biomarkers as quantitative phenotypes: Genetics core aims, progress, and plans. Alzheimers Dement 2010 2.79
11 Disclosing pathogenic genetic variants to research participants: quantifying an emerging ethical responsibility. Genome Res 2012 2.76
12 Point-counterpoint. Ethics and genomic incidental findings. Science 2013 2.73
13 Variants in the ATP-binding cassette transporter (ABCA7), apolipoprotein E ϵ4,and the risk of late-onset Alzheimer disease in African Americans. JAMA 2013 2.58
14 Who seeks genetic susceptibility testing for Alzheimer's disease? Findings from a multisite, randomized clinical trial. Genet Med 2004 2.44
15 The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement 2013 2.32
16 Health behavior changes after genetic risk assessment for Alzheimer disease: The REVEAL Study. Alzheimer Dis Assoc Disord 2008 2.30
17 Hippocampal sclerosis in advanced age: clinical and pathological features. Brain 2011 2.16
18 Processes and preliminary outputs for identification of actionable genes as incidental findings in genomic sequence data in the Clinical Sequencing Exploratory Research Consortium. Genet Med 2013 2.08
19 Novel late-onset Alzheimer disease loci variants associate with brain gene expression. Neurology 2012 2.08
20 Genetic risk assessment for adult children of people with Alzheimer's disease: the Risk Evaluation and Education for Alzheimer's Disease (REVEAL) study. J Geriatr Psychiatry Neurol 2005 2.03
21 Direct to consumer genetic testing: Avoiding a culture war. Genet Med 2009 2.00
22 Genetic testing for Alzheimer's disease and its impact on insurance purchasing behavior. Health Aff (Millwood) 2005 1.93
23 Extended results of the Alzheimer's disease anti-inflammatory prevention trial. Alzheimers Dement 2011 1.87
24 Methodological Considerations in Studying Centenarians: Lessons Learned From the Georgia Centenarian Studies. Annu Rev Gerontol Geriatr 2007 1.85
25 Progression of cognitive, functional, and neuropsychiatric symptom domains in a population cohort with Alzheimer dementia: the Cache County Dementia Progression study. Am J Geriatr Psychiatry 2011 1.83
26 Reasons for seeking genetic susceptibility testing among first-degree relatives of people with Alzheimer disease. Alzheimer Dis Assoc Disord 2003 1.79
27 Diabetes mellitus and risk of developing Alzheimer disease: results from the Framingham Study. Arch Neurol 2006 1.78
28 Trail Making Test errors in normal aging, mild cognitive impairment, and dementia. Arch Clin Neuropsychol 2008 1.69
29 Genetic testing for Alzheimer's and long-term care insurance. Health Aff (Millwood) 2010 1.67
30 Using AD biomarker research results for clinical care: a survey of ADNI investigators. Neurology 2013 1.63
31 Regulation: The FDA is overcautious on consumer genomics. Nature 2014 1.52
32 Epidemiology of apathy in older adults: the Cache County Study. Am J Geriatr Psychiatry 2007 1.50
33 Disclosing Pleiotropic Effects During Genetic Risk Assessment for Alzheimer Disease: A Randomized Trial. Ann Intern Med 2016 1.47
34 Personalized genetic risk counseling to motivate diabetes prevention: a randomized trial. Diabetes Care 2012 1.46
35 The future of direct-to-consumer clinical genetic tests. Nat Rev Genet 2011 1.38
36 Association between apolipoprotein E genotype and Alzheimer disease in African American subjects. Arch Neurol 2002 1.37
37 The effect of TOMM40 poly-T length on gray matter volume and cognition in middle-aged persons with APOE ε3/ε3 genotype. Alzheimers Dement 2011 1.35
38 The adult galactosemic phenotype. J Inherit Metab Dis 2011 1.34
39 Caregiver-recipient closeness and symptom progression in Alzheimer disease. The Cache County Dementia Progression Study. J Gerontol B Psychol Sci Soc Sci 2009 1.33
40 Clock drawing test ratings by dementia specialists: interrater reliability and diagnostic accuracy. J Neuropsychiatry Clin Neurosci 2010 1.33
41 Communicating genetic risk information for common disorders in the era of genomic medicine. Annu Rev Genomics Hum Genet 2013 1.33
42 A comprehensive genetic association study of Alzheimer disease in African Americans. Arch Neurol 2011 1.33
43 Genome-wide scan of healthy human connectome discovers SPON1 gene variant influencing dementia severity. Proc Natl Acad Sci U S A 2013 1.26
44 Genetic susceptibility testing for Alzheimer disease: motivation to obtain information and control as precursors to coping with increased risk. Patient Educ Couns 2006 1.26
45 Cognitive correlates of HVOT performance differ between individuals with mild cognitive impairment and normal controls. Arch Clin Neuropsychol 2006 1.26
46 The role of apolipoprotein E (APOE) genotype in early mild cognitive impairment (E-MCI). Front Aging Neurosci 2013 1.26
47 Development and validation of a computational method for assessment of missense variants in hypertrophic cardiomyopathy. Am J Hum Genet 2011 1.25
48 Effect of Alzheimer disease genetic risk disclosure on dietary supplement use. Am J Clin Nutr 2010 1.25
49 Predictive genetic testing for Alzheimer's disease: impact upon risk perception. Risk Anal 2005 1.25
50 Diagnostic clinical genome and exome sequencing. N Engl J Med 2014 1.24
51 Genetic analysis of quantitative phenotypes in AD and MCI: imaging, cognition and biomarkers. Brain Imaging Behav 2014 1.23
52 Population-based study of medical comorbidity in early dementia and "cognitive impairment, no dementia (CIND)": association with functional and cognitive impairment: The Cache County Study. Am J Geriatr Psychiatry 2005 1.23
53 Differences between African Americans and whites in their perceptions of Alzheimer disease. Alzheimer Dis Assoc Disord 2003 1.21
54 "I know what you told me, but this is what I think:" perceived risk of Alzheimer disease among individuals who accurately recall their genetics-based risk estimate. Genet Med 2010 1.19
55 Lower-extremity function in cognitively healthy aging, mild cognitive impairment, and Alzheimer's disease. Arch Phys Med Rehabil 2010 1.18
56 Genetic susceptibility testing versus family history-based risk assessment: Impact on perceived risk of Alzheimer disease. Genet Med 2005 1.17
57 The beliefs, motivations, and expectations of parents who have enrolled their children in a genetic biorepository. Genet Med 2012 1.17
58 Differences between African Americans and Whites in their attitudes toward genetic testing for Alzheimer's disease. Genet Test 2003 1.16
59 Association of distinct variants in SORL1 with cerebrovascular and neurodegenerative changes related to Alzheimer disease. Arch Neurol 2008 1.16
60 A new scale measuring psychologic impact of genetic susceptibility testing for Alzheimer disease. Alzheimer Dis Assoc Disord 2009 1.16
61 A systematic approach to the reporting of medically relevant findings from whole genome sequencing. BMC Med Genet 2014 1.14
62 Health-care referrals from direct-to-consumer genetic testing. Genet Test Mol Biomarkers 2010 1.13
63 Navigating a research partnership between academia and industry to assess the impact of personalized genetic testing. Genet Med 2012 1.11
64 Polymorphisms in the PON gene cluster are associated with Alzheimer disease. Hum Mol Genet 2005 1.08
65 Incorporating ethnicity into genetic risk assessment for Alzheimer disease: the REVEAL study experience. Genet Med 2008 1.08
66 ABCC9 gene polymorphism is associated with hippocampal sclerosis of aging pathology. Acta Neuropathol 2014 1.07
67 Test-retest stability on the WRAT-3 reading subtest in geriatric cognitive evaluations. J Clin Exp Neuropsychol 2008 1.06
68 Willingness to pay for genetic testing for Alzheimer's disease: a measure of personal utility. Genet Test Mol Biomarkers 2011 1.06
69 Nonsteroidal anti-inflammatory drug use and Alzheimer's disease risk: the MIRAGE Study. BMC Geriatr 2005 1.03
70 Recall of disclosed apolipoprotein E genotype and lifetime risk estimate for Alzheimer's disease: the REVEAL Study. Genet Med 2006 1.03
71 Relationship between Serum and Brain Carotenoids, α-Tocopherol, and Retinol Concentrations and Cognitive Performance in the Oldest Old from the Georgia Centenarian Study. J Aging Res 2013 1.03
72 Diagnostic utility of the NAB List Learning test in Alzheimer's disease and amnestic mild cognitive impairment. J Int Neuropsychol Soc 2009 1.02
73 The Framingham Brain Donation Program: neuropathology along the cognitive continuum. Curr Alzheimer Res 2012 1.02
74 GINA, genism, and civil rights. Bioethics 2008 1.02
75 Heritability of magnetic resonance imaging (MRI) traits in Alzheimer disease cases and their siblings in the MIRAGE study. Alzheimer Dis Assoc Disord 2007 1.02
76 Characterizing genetic variants for clinical action. Am J Med Genet C Semin Med Genet 2014 1.02
77 Comparing test-specific distress of susceptibility versus deterministic genetic testing for Alzheimer's disease. Alzheimers Dement 2008 1.00
78 Education effects on cognitive function in a healthy aged Arab population. Int Psychogeriatr 2006 1.00
79 Magnetic resonance imaging traits in siblings discordant for Alzheimer disease. J Neuroimaging 2008 0.99
80 Performance of ACMG-AMP Variant-Interpretation Guidelines among Nine Laboratories in the Clinical Sequencing Exploratory Research Consortium. Am J Hum Genet 2016 0.99
81 The role of disease perceptions and results sharing in psychological adaptation after genetic susceptibility testing: the REVEAL Study. Eur J Hum Genet 2010 0.98
82 Geriatric performance on an abbreviated version of the Boston naming test. Appl Neuropsychol 2007 0.97
83 Research results: preserving newborn blood samples. Sci Transl Med 2012 0.97
84 Association of common genetic variants in GPCPD1 with scaling of visual cortical surface area in humans. Proc Natl Acad Sci U S A 2012 0.95
85 Effectiveness of a condensed protocol for disclosing APOE genotype and providing risk education for Alzheimer disease. Genet Med 2012 0.95
86 Clock drawing performance in cognitively normal elderly. Arch Clin Neuropsychol 2008 0.94
87 How Well Do Customers of Direct-to-Consumer Personal Genomic Testing Services Comprehend Genetic Test Results? Findings from the Impact of Personal Genomics Study. Public Health Genomics 2015 0.93
88 Effects of general medical health on Alzheimer's progression: the Cache County Dementia Progression Study. Int Psychogeriatr 2012 0.92
89 A one-page summary report of genome sequencing for the healthy adult. Public Health Genomics 2015 0.92
90 Design of a randomized trial of diabetes genetic risk testing to motivate behavior change: the Genetic Counseling/lifestyle Change (GC/LC) Study for Diabetes Prevention. Clin Trials 2011 0.91
91 Changes to perceptions of the pros and cons of genetic susceptibility testing after APOE genotyping for Alzheimer disease risk. Genet Med 2011 0.90
92 Management of incidental findings in clinical genomic sequencing. Curr Protoc Hum Genet 2013 0.90
93 Direct-to-consumer genetic testing: reliable or risky? Clin Chem 2011 0.89
94 Differences between African American and White research volunteers in their attitudes, beliefs and knowledge regarding genetic testing for Alzheimer's disease. J Genet Couns 2011 0.89
95 Perceptions of familial risk in those seeking a genetic risk assessment for Alzheimer's disease. J Genet Couns 2008 0.89
96 Explaining behavior change after genetic testing: the problem of collinearity between test results and risk estimates. Genet Test 2008 0.89
97 How could disclosing incidental information from whole-genome sequencing affect patient behavior? Per Med 2013 0.89
98 Education attenuates the effect of medial temporal lobe atrophy on cognitive function in Alzheimer's disease: the MIRAGE study. J Alzheimers Dis 2009 0.88
99 Attitudes about regulation among direct-to-consumer genetic testing customers. Genet Test Mol Biomarkers 2013 0.88
100 Consumer Perceptions of Interactions With Primary Care Providers After Direct-to-Consumer Personal Genomic Testing. Ann Intern Med 2016 0.88
101 Common folate gene variant, MTHFR C677T, is associated with brain structure in two independent cohorts of people with mild cognitive impairment. Neuroimage Clin 2012 0.88
102 Vascular factors and risk for neuropsychiatric symptoms in Alzheimer's disease: the Cache County Study. Int Psychogeriatr 2008 0.88
103 Use of statins and risk of hospitalization with dementia: a Danish population-based case-control study. Alzheimer Dis Assoc Disord 2009 0.87
104 Disclosing the disclosure: factors associated with communicating the results of genetic susceptibility testing for Alzheimer's disease. J Health Commun 2009 0.87
105 Interaction between vascular factors and the APOE ε4 allele in predicting rate of progression in Alzheimer's disease. J Alzheimers Dis 2011 0.87
106 Association of TTR polymorphisms with hippocampal atrophy in Alzheimer disease families. Neurobiol Aging 2009 0.86
107 Prioritizing disease-linked variants, genes, and pathways with an interactive whole-genome analysis pipeline. Hum Mutat 2014 0.85
108 Genetic susceptibility for Alzheimer's disease: why did adult offspring seek testing? Am J Alzheimers Dis Other Demen 2006 0.84
109 Profiles of cognitive functioning in a population-based sample of centenarians using factor mixture analysis. Exp Aging Res 2013 0.82
110 Calibrating longitudinal cognition in Alzheimer's disease across diverse test batteries and datasets. Neuroepidemiology 2014 0.82
111 Genetic susceptibility testing for chronic disease and intention for behavior change in healthy young adults. J Community Genet 2013 0.81
112 Predicting cognitive decline and conversion to Alzheimer's disease in older adults using the NAB List Learning test. J Int Neuropsychol Soc 2010 0.80
113 Predictors of subjective memory complaint in cognitively normal relatives of patients with Alzheimer's disease. J Neuropsychiatry Clin Neurosci 2006 0.79
114 Effects of Food and Drug Administration-approved medications for Alzheimer's disease on clinical progression. Alzheimers Dement 2012 0.79
115 Serum paraoxonase activity is associated with variants in the PON gene cluster and risk of Alzheimer disease. Neurobiol Aging 2010 0.79
116 Reducing false-positive incidental findings with ensemble genotyping and logistic regression based variant filtering methods. Hum Mutat 2014 0.79
117 The ADNI Publication Policy: commensurate recognition of critical contributors who are not authors. Neuroimage 2011 0.79
118 Successful Recruitment of Centenarians for Post-Mortem Brain Donation: Results from the Georgia Centenarian Study. J Biosci Med 2012 0.78
119 Diagnostic accuracy statistics for seven Neuropsychological Assessment Battery (NAB) test variables in the diagnosis of Alzheimer's disease. Appl Neuropsychol Adult 2012 0.77
120 Areas of intervention for genetic counselling of dementia: cross-cultural comparison between Italians and Americans. Patient Educ Couns 2006 0.77
121 A randomized trial of the clinical utility of genetic testing for obesity: design and implementation considerations. Clin Trials 2013 0.77
122 Clinical Sequencing Exploratory Research Consortium: Accelerating Evidence-Based Practice of Genomic Medicine. Am J Hum Genet 2016 0.77
123 Genomic medicine in primary care: barriers and assets. Postgrad Med J 2013 0.76
124 The structure and validity of self-reported affect in mild cognitive impairment and mild Alzheimer's disease. Int Psychogeriatr 2011 0.76
125 Caregiver personality predicts rate of cognitive decline in a community sample of persons with Alzheimer's disease. The Cache County Dementia Progression Study. Int Psychogeriatr 2013 0.75
126 Minding the aging brain: are we ready for personalized medicine? Am J Psychiatry 2014 0.75
127 APOE ϵ4, rated life experiences, and affect among centenarians. Aging Ment Health 2013 0.75
128 Factors affecting recall of different types of personal genetic information about Alzheimer's disease risk: the REVEAL study. Public Health Genomics 2015 0.75
129 Implications of Personal Genomic Testing for Health Behaviors: The Case of Smoking. Nicotine Tob Res 2016 0.75
130 Direct-to-Consumer Genetic Testing: User Motivations, Decision Making, and Perceived Utility of Results. Public Health Genomics 2017 0.75